Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vibecotamab
- Development stage
- Discontinued
- Lead developer
- Xencor
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vibecotamab (XmAb14045) is a humanized bispecific monoclonal antibody designed to target both CD123 and CD3. It binds monovalently to the interleukin-3 receptor subunit alpha (CD123) on tumor cells and the T cell surface glycoprotein CD3 on cytotoxic T cells. This dual binding recruits and activates T cells to mediate targeted killing of CD123-expressing tumor cells, particularly in acute myeloid leukemia (AML) and other hematologic malignancies. Developed using Xencor’s XmAb bispecific Fc domain technology, it offers extended half-life and stability for therapeutic use[1][2][3][4][5][6][7].
- Other names
- vibecotamabXmAb 14045XmAb14045XmAb-14045
02
Targets
IL3RA (Interleukin 3 Receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on vibecotamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vibecotamab.